Amneal Pharmaceuticals
AMRX

$8.39

0.71%

Market Cap: $2.6B

About: Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 7,700

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

339% more call options, than puts

Call options by funds: $1.56M | Put options by funds: $355K

61% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 44

36% more capital invested

Capital invested by funds: $657M [Q1] → $891M (+$234M) [Q2]

17% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 30

10.43% more ownership

Funds ownership: 35.36% [Q1] → 45.79% (+10.43%) [Q2]

3% more funds holding

Funds holding: 175 [Q1] → 180 (+5) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

7%

upside

Avg. target

$9.67

15%

upside

High target

$10

19%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

JP Morgan Chris Schott 73% 1-year accuracy 8 / 11 met price target	7%upside $9	Neutral Upgraded	6 Sept 2024
Barclays Balaji Prasad 49% 1-year accuracy 17 / 35 met price target	19%upside $10	Overweight Maintained	13 Aug 2024
Truist Securities Les Sulewski 67% 1-year accuracy 4 / 6 met price target	19%upside $10	Buy Maintained	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about AMRX published over the past 30 days

Zacks Investment Research

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates

AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates

Zacks Investment Research

Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock

Melina Kennedy Joins the LDI, Ltd. Board of Managers

INDIANAPOLIS--(BUSINESS WIRE)--LDI, Ltd., a leading family office, is proud to announce the election of Melina Kennedy to its Board of Managers. Kennedy is currently the Chief Executive Officer of the Central Indiana Corporate Partnership (CICP), a collaboration of CEOs from major corporations, foundations, and universities dedicated to advancing inclusive prosperity through strategic initiatives and investments in Indiana. "We are thrilled to welcome Melina to our board," said J.A. Lacy, CEO,.

Melina Kennedy Joins the LDI, Ltd. Board of Managers

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (FDA) for Propofol Injectable Emulsion USP, 200 mg/20 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL), and 1,000 mg/100 mL (10 mg/mL), Single-Dose Vials. Propofol is an intravenous drug commonly used in hospitals for the induction and maintenance of anesthesia and seda.

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Zacks Investment Research

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Operator Good morning and welcome to the Amneal Pharmaceuticals Second Quarter 2024 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?

Zacks Investment Research

Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.19 per share a year ago.

Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates

Amneal Reports Second Quarter 2024 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2024. “Amneal achieved strong revenues and adjusted EBITDA in the second quarter, and we are pleased to raise full year 2024 guidance driven by broad-based growth across our business. Amneal is a diversified and growing global pharmaceuticals company built on our core strengths in quality, innovation and operational executi.

Amneal Reports Second Quarter 2024 Financial Results

See News Rankings